Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies.

1] Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA [2] Department of Medical Oncology and Experimental Therapeutics, City of Hope, Duarte, CA, USA.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 9.38). 11/2012; DOI: 10.1038/leu.2012.311
Source: PubMed

ABSTRACT The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44% of the cohort) were observed: 78% attributed to recurrent disease; 9% to subsequent malignancies and 6% to cardiopulmonary disease. Estimated probability of relative survival was 62% at 5 years and 50% at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88% after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95% confidence interval (CI)=13.1-14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95% CI=0.9-1.9), with the exception of female Hodgkin's lymphoma patients transplanted before 1995 at age 40 years (SMR=6.0, 95% CI=1.9-14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.Leukemia advance online publication, 27 November 2012; doi:10.1038/leu.2012.311.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Current recommendations for monitoring patients with chronic myeloid leukemia (CML) provide recommendations for response assessment and treatment only at 3, 6, 12, and 18 months. These recommendations are based on clinical trial outcomes computed from treatment start. Conditional survival estimates take into account the changing hazard rates as time from treatment elapses as a continuum. We performed conditional survival analyses among patients with CML to improve prognostication at any time point during the course of therapy. We used two cohorts of patients with CML in chronic phase: one treated in the frontline DASISION phase III study (n=519) and another treated after imatinib failure in the dasatinib dose-optimization phase III CA180-034 study (n=670). Conditional survival estimates were calculated. A modified Cox proportional hazards model was used to build a prognostic nomogram. As the time alive or free from events from commencement of treatment increased, conditional survival estimates changed. No differences were observed regarding future outcomes between patients treated with imatinib or dasatinib in the frontline setting for patients with the same BCR-ABL1 transcript levels evaluated at the same time-point. Age over 60 years greatly impacted future outcomes particularly in the short-term. Conditional survival-based nomograms allowed the prediction of future outcomes at any time-point. In summary, we designed a calculator to predict future outcomes of patients with CML at any time-point during the course of therapy.
    Clinical lymphoma, myeloma & leukemia 08/2014; DOI:10.1016/j.clml.2014.01.003 · 1.93 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014